IMD publications

IMD peer reviewed articles:

  1. Grunberger G, Rosenfeld CR, Bode BW, Abbott SD, Nikkel C, Shi L, Strange P. Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study. Drugs - Real World Outcomes. 2019:7(1), 31-40.
  2. Macdonald RL, Hänggi D, Strange P, Steiger HJ, Mocco J, Miller M, Mayer SA, Hoh BL, Faleck HJ, Etminan N, Diringer MN, Carlson AP, Aldrich F and the NEWTON Investigators. Nimodipine pharmacokinetics after intraventricular injection of sustained-release nimodipine for subarachnoid hemorrhage. Journal of Neurosurgery. 2019: 1-7. https://doi.org/10.3171/2019.9.JNS191366.
  3. Cziraky MJ, Abbott S, Nguyen M, Larholt K, Apgar E, Wasser T, Strange P, Shi L, Harrison HC, Everitt B, Nowak L. A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes. Journal of Health Economics and Outcomes Research. 2019; 6(2): 70-83.
  4. Henry RR, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov SB, Mansfield T, Klein D, Katz A. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. 2018; 20(11):715-24.
  5. Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, Huffman D, Strange P, Öhman P. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study. Diabetes Care. 2018; 41: 2346-52.
  6. Laguna Sanz AJ, Mulla CM, Fowler KM, Cloutier E, Goldfine AB, Newswanger B, Cummins M, Deshpande S, Prestrelski SJ, Strange P, Zisser H, Doyle FJ 3rd, Dassau E, Patti ME. Diabetes Technol Ther. 2018; 20 (2):127-139.
  7. Juan P. Frías, Samer Nakhle, James A. Ruggles, Sergey Zhuplatov, Eric Klein, Rong Zhou, Poul Strange. Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017; 19 (1):40-48.
  8. Castle JR, Youssef JE, Branigan D, Newswanger B, Strange P, Cummins M, Shi L, Prestrejlski S. Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects. J Diabetes Sci Technol. 2016 Aug 22; 10(5): 1101-7.
  9. Hänggi D1, Etminan N, Macdonald RL, Steiger HJ, Mayer SA, Aldrich F, Diringer MN, Hoh BL, Mocco J, Strange P, Faleck HJ, Miller M. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage. Neurocrit Care. 2015; 32(2): 274-84.
  10. Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Arteriosclerosis, Thrombosis and Vascular Biology. 2014; 34:676-83.
  11. Rosenfeld CR, Bohannon NJ, Bode B, Kelman, AS, Mintz SN, Schorr AB, Sandberg MI, Nambi S, Agarwala SK, Leicther SB, Larrabee b, Shi L, Strange P. Endocrine Practice. 2012; 18, 660-7.
  12. Penckofer S, Quinn L, Byrn M, Ferrans C, Miller M, Strange P. Does Glycemic Variability Impact Mood and Quality of Life? Diabetes Technology & Therapeutics 2012: 1(4), 1-8.
  13. Stote R, Marbury T, Shi L, Miller M, Strange P. Enhanced Absorption of Nasulin™, an Ultrarapid-Acting Intranasal Insulin Formulation, Using Single Nostril Administration in Normal Subjects. Journal of Diabetes Science and Technology. 2011:5(1), 113-9.
  14. Stote R, Marbury T, Shi L, Miller M, Strange P. Comparison Pharmacokinetics of Two Concentrations (0.7% and 1.0%) of NasulinTM, an Ultra-Rapid-Acting Intranasal Insulin Formulation. Journal of Diabetes Science and Technology. 2010:4(3), 603-9.
  15. Dailey G, Strange P, Riddle M. Reconsideration of Severe Hypoglycemic Events in the Treat-to-Target Trial. Diabetes Technology & Therapeutics 2009; 11(8): 477-79
  16. Dailey G, Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Am J Manag Care. 2008: 14, 25-30.
  17. Kapitza C, Fein S, Heinemann L, Schleusener S, Levesque S, Strange P. Basal–Prandial Insulin Delivery in Type 2 Diabetes Mellitus via the V-Go: A Novel Continuous Subcutaneous Infusion Device. Journal of Diabetes Science and Technology. 2008:2(1), 40-46.
  18. Strange P. Treat-to-Target Insulin Titration Algorithms When Initiating Long or Intermediate Acting Insulin in Type 2 Diabetes. Journal of Diabetes Science and Technology. Volume 1, Issue 4, July 2007; 1(4): 540-548.